The global leukapheresis market is becoming increasingly important as healthcare providers, blood centers, pharmaceutical companies, biotechnology companies, and cell therapy developers expand the use of leukocyte collection in therapeutic and research applications. Leukapheresis plays a critical role in the collection of white blood cells for hematological treatments, immune-cell research, transplantation, and the manufacturing of advanced cell and gene therapies.

The global leukapheresis market was valued at approximately USD 83.3 million in 2025 and is projected to reach USD 138.7 million by 2031, expanding at a CAGR of 8.9% during 2026–2031. The market was estimated at USD 90.6 million in 2026. Growth is being supported by increasing demand for leukocyte collection in hematological disorders, the expansion of CAR-T, TCR, and NK-cell therapies, growing clinical-trial activity, and investments in cell and gene therapy manufacturing infrastructure. 

The leukapheresis ecosystem is also expanding beyond conventional therapeutic apheresis. Research organizations and cell therapy manufacturers increasingly require high-quality leukopaks as starting materials for T-cell isolation, PBMC processing, immune-cell characterization, gene editing, and cell therapy development. Companies such as STEMCELL Technologies, Charles River Laboratories, CGT Global, OrganaBio, Sanguine Biosciences, and AcceGen have developed or expanded leukopak and human-cell sourcing capabilities to address these requirements. 

Technology development is increasingly focused on automated and continuous-flow collection, improved donor safety, disposable apheresis sets, higher collection efficiency, process standardization, and integration with cell-processing workflows. At the same time, the rapid growth of cell and gene therapy is creating demand for fresh, frozen, mobilized, disease-state, and GMP-compatible leukopaks that can be incorporated into research and manufacturing workflows.

Against this background, the following 32 companies represent a cross-section of organizations active across leukapheresis equipment, apheresis consumables, blood-component processing, leukopak sourcing, cell therapy starting materials, and related cell-processing applications.

1. Terumo Corporation

Terumo is one of the most prominent companies in the leukapheresis and apheresis ecosystem, with its Terumo Blood and Cell Technologies business serving blood centers, hospitals, and cell therapy workflows.

The company’s apheresis platforms support collection and processing of blood components and cellular products, making Terumo particularly relevant to the growing requirement for standardized leukocyte collection. Its extensive installed base and presence across hospitals and blood centers are key factors behind its positioning as a leading leukapheresis player. MarketsandMarkets identifies Terumo BCT as a star performer in the leukapheresis market. 

2. Fresenius SE & Co. KGaA

Fresenius participates in the leukapheresis market primarily through Fresenius Kabi, whose apheresis and blood-processing activities serve hospitals, blood banks, and cellular therapy applications.

The company benefits from an established presence in medical devices, transfusion medicine, and cell-processing workflows. Fresenius Kabi is identified by MarketsandMarkets alongside Terumo BCT as one of the leading companies in the leukapheresis market, supported by its installed base and adoption across healthcare facilities. 

3. Haemonetics Corporation

Haemonetics is an established participant in the blood-management and apheresis equipment market, with technologies designed for blood collection, processing, and component management.

Its apheresis capabilities position the company within therapeutic and donor-collection workflows, while continued emphasis on automation and collection efficiency aligns with the market’s movement toward standardized cellular collection. MarketsandMarkets identifies Haemonetics as one of the major leukapheresis companies. 

4. Nikkiso Co., Ltd.

Nikkiso participates in the blood-component and apheresis equipment ecosystem through technologies used in cellular and blood-processing applications.

Its presence is particularly relevant to the Asian market, where healthcare infrastructure, blood-component processing capabilities, and cell therapy activity are expanding. MarketsandMarkets lists Nikkiso among the key players in the global leukapheresis market. 

5. Sumitomo Bakelite Co., Ltd.

Sumitomo Bakelite participates in healthcare and life-science applications through advanced materials, medical products, and technologies used in highly controlled biological and clinical workflows.

Its relevance to the leukapheresis ecosystem is connected to the broader development of medical consumables and cell-processing technologies. Increasing demand for single-use, standardized components in cellular workflows creates opportunities for specialized materials manufacturers.

6. Danaher Corporation

Danaher has exposure to the leukapheresis and cell-processing ecosystem through its broad portfolio of life-science, diagnostics, biotechnology, and bioprocessing businesses.

The company’s relevance extends beyond the collection device itself to downstream cell-processing and analytical workflows. This is increasingly important as leukapheresis becomes integrated with cell and gene therapy manufacturing, where collected leukocytes must be processed, characterized, activated, expanded, or genetically modified.

7. Otsuka Holdings Co., Ltd.

Otsuka participates in healthcare and life sciences across pharmaceuticals, medical products, diagnostics, and biotechnology.

Its broader healthcare footprint positions it within the expanding ecosystem surrounding hematology, oncology, cellular therapies, and advanced biomedical research. The growing convergence between leukapheresis, immune-cell collection, and cell therapy development creates opportunities for diversified healthcare companies with capabilities across multiple stages of the therapeutic value chain.

8. Asahi Kasei Medical Co., Ltd.

Asahi Kasei Medical is active in blood-related medical technologies, including products and systems supporting blood purification and therapeutic applications.

Its expertise in blood processing and extracorporeal technologies provides a foundation for participation in the broader apheresis ecosystem. Growth in therapeutic apheresis and advanced cellular processing is increasing the importance of technologies capable of efficiently separating and handling specific blood components.

9. Macopharma SA

Macopharma is a major European participant in transfusion medicine and blood-component processing.

The company develops blood bags, collection systems, and technologies supporting blood component separation and processing. Its established presence in blood centers and transfusion workflows makes it relevant to leukapheresis consumables and related cellular collection applications. MarketsandMarkets identifies Macopharma among the major players in the leukapheresis market. 

10. Medica S.p.A.

Medica is an Italian medical technology company with activities spanning blood processing, filtration, and extracorporeal technologies.

Its capabilities in membrane and filtration technologies are relevant to the broader leukapheresis and blood-component processing market. MarketsandMarkets includes Medica among the key players in the global leukapheresis landscape. 

11. Polymed

Poly Medicure, commonly known as Polymed, is an India-based medical-device manufacturer with a broad portfolio of disposable medical products.

The company’s capabilities in single-use medical devices and consumables are relevant to the growing requirement for disposable components throughout blood collection and processing workflows. Demand for cost-effective and scalable disposable medical technologies is particularly important in emerging markets.

12. Puriblood Medical

Puriblood Medical represents the specialized medical-device segment supporting blood processing and apheresis-related workflows.

Companies operating in this segment benefit from the growing requirement for safe, standardized, single-use products as hospitals and blood centers modernize collection and component-processing infrastructure. The increasing use of disposable systems also helps reduce cross-contamination risks and simplify workflow management.

13. Guangzhou Daji Medical Science and Technology Co., Ltd.

Guangzhou Daji Medical Science and Technology participates in China’s expanding medical-device ecosystem.

Its relevance to the leukapheresis market reflects the increasing development of domestic medical technologies and blood-processing capabilities in China. Growth in Chinese clinical trials, cell therapy development, and specialized hospital infrastructure is expected to support demand for apheresis and related consumables across Asia Pacific.

14. Safetran Biomedical Inc.

Safetran Biomedical operates in the medical-device and blood-processing ecosystem, with relevance to technologies supporting blood collection and cellular-processing workflows.

The company’s positioning reflects the broader shift toward specialized and disposable products required for modern blood-component and cellular therapy applications. Demand for reliable collection and processing systems is expected to increase alongside cell therapy development.

15. Mitra Industries Private Limited

Mitra Industries is an India-based medical-device company with capabilities spanning blood banking, transfusion medicine, and related equipment.

Its presence is particularly relevant as India develops more sophisticated blood-component processing and cell therapy infrastructure. Increasing investment in hospitals, blood centers, and advanced therapies is creating additional opportunities for domestic suppliers of blood-processing technologies.

16. Lonza

Lonza is one of the world’s major life-science and cell-and-gene-therapy manufacturing companies.

Its role in the leukapheresis ecosystem is particularly important on the downstream side: leukapheresis-derived cells are increasingly used as starting materials for cell therapy development and manufacturing. MarketsandMarkets identifies Lonza among the significant players in the leukopak market, alongside companies such as Grifols, Charles River Laboratories, STEMCELL Technologies, and BioIVT. 

17. Grifols

Grifols has a longstanding presence in plasma, blood products, transfusion medicine, and healthcare technologies.

Its position in the leukapheresis ecosystem extends into leukopak and cellular starting-material applications. MarketsandMarkets identifies Grifols among the leading leukapheresis companies and also includes it among significant participants in the leukopak market. 

18. Charles River Laboratories

Charles River has expanded its role in advanced therapies through human-cell sourcing and services for cell and gene therapy research.

The company offers fresh and cryopreserved leukopaks, including disease-state and mobilized leukopaks, supporting basic research and GMP-compliant cellular starting-material requirements. Charles River reports that its leukopaks can contain millions to billions of white blood cells, with collections typically averaging approximately 10–13 billion WBCs. 

This positions Charles River at the interface between leukapheresis collection and downstream advanced-therapy development.

19. Cellex Cell Professionals

Cellex Cell Professionals is associated with specialized cellular and blood-derived starting materials for research and advanced cell therapy applications.

The company’s positioning reflects a growing industry segment in which specialized collection organizations provide researchers and biotechnology companies with high-quality human cellular material. Such suppliers help bridge the gap between donor collection and downstream cell-processing workflows.

20. STEMCELL Technologies

STEMCELL Technologies is a major supplier of human primary cells and leukopaks for biomedical research.

Its peripheral blood leukopak portfolio includes fresh and frozen products, normal and disease-state samples, and mobilized leukopaks. The company states that full-sized leukopaks typically contain more than 9 billion cells and can be used for applications including adoptive cell therapy, TCR research, and immunotherapy development. 

STEMCELL’s ability to provide different leukopak sizes, donor characteristics, HLA information, and downstream cell-isolation solutions strengthens its role in the research-focused leukopak market.

21. BioIVT

BioIVT is a major provider of biospecimens and research services, supplying human blood-derived materials to pharmaceutical, biotechnology, and academic researchers.

Its broader biospecimen platform supports research requiring consistent human biological starting materials. As cell and gene therapy programs increasingly require donor-derived immune cells and PBMCs, biospecimen providers such as BioIVT occupy an increasingly important position within the leukopak ecosystem. 

22. Discovery Life Sciences

Discovery Life Sciences provides biospecimens, laboratory services, and cell-based research solutions to pharmaceutical and biotechnology companies.

Its role in the leukapheresis ecosystem is primarily associated with human biospecimen and cellular-material sourcing rather than the manufacture of apheresis machines. The expansion of cell therapy research increases demand for well-characterized human immune-cell starting materials, creating opportunities for companies with integrated biospecimen and laboratory capabilities.

23. Miltenyi Biotec

Miltenyi Biotec is a major life-science company specializing in cell separation, cell analysis, and cell therapy technologies.

Its technologies are particularly relevant to leukapheresis-derived material because leukopaks often serve as the starting material for isolation of T cells, NK cells, B cells, monocytes, and other cellular populations. MarketsandMarkets describes Miltenyi Biotec as an emerging leader in the leukapheresis market as its focus on cell and gene therapy has increased its prominence. 

24. StemVivo Inc.

StemVivo provides human primary cells and blood-derived research products, including fresh peripheral blood leukopaks.

Its leukopak products are collected from normal donors and are intended for applications including CAR-T research, T-cell biology, B-cell research, macrophage studies, and NK-cell research. StemVivo states that its leukopaks are collected using Spectra Optia apheresis systems under IRB-approved protocols. 

25. CGT Global

CGT Global is focused on human-cell sourcing and starting materials for cell and gene therapy research, development, and manufacturing.

Its leukopak portfolio includes fresh, cryopreserved, mobilized, disease-state, and GMP-grade products. The company reports that its leukopaks are collected at FDA-registered collection clinics and can be supplied with donor characterization, infectious-disease screening, HLA typing, and other customized requirements. 

This makes CGT Global particularly relevant to the transition from research-scale leukopak use toward translational and clinical cell therapy workflows.

26. Sanguine Biosciences

Sanguine Biosciences specializes in prospective human biospecimen collection and donor-based research materials.

Its leukopak capabilities include fresh and cryopreserved leukapheresis products sourced from donors through qualified apheresis clinics. The company highlights applications in assay validation, process development, biomarker research, and cell and gene therapy. 

Its large donor network and ability to link leukapheresis products with donor medical information can be valuable for disease-specific and translational research.

27. Biomex GmbH

Biomex participates in the human biospecimen and cell-based research ecosystem, supplying biological materials and services to researchers.

Its relevance to the leukapheresis market comes from the growing requirement for high-quality human primary cells and immune-cell materials for drug discovery, immunology, diagnostics, and advanced-therapy research.

As research moves toward more physiologically representative human models, suppliers of donor-derived cellular material are becoming increasingly important to the leukopak value chain.

28. AcceGen

AcceGen is a supplier of human primary cells and disease-specific cellular research products.

Its portfolio includes leukopaks from donors with specific disease states, including autoimmune and inflammatory conditions. For example, AcceGen offers leukopaks associated with osteoarthritis and psoriasis research, providing immune-cell-rich material for disease-mechanism studies, biomarker research, and therapeutic development. 

This disease-state focus differentiates AcceGen from suppliers concentrating primarily on healthy-donor leukopaks.

29. Excellos

Excellos operates in the cell therapy and cellular-processing ecosystem, supporting development and manufacturing activities involving immune and other therapeutic cell populations.

Its relevance to leukapheresis is driven by the role of leukapheresis-derived cells as starting materials for cell therapy workflows. As developers seek to move from early research toward scalable manufacturing, integrated cell-processing capabilities become increasingly important.

30. First Choice Bio Inc.

First Choice Bio participates in the human biospecimen and cellular-material supply ecosystem.

Its relevance to leukapheresis reflects the expanding requirement for high-quality human blood-derived starting materials for pharmaceutical, biotechnology, and academic research. The growth of immunotherapy and cell therapy programs is increasing demand for consistent donor-derived immune-cell products.

31. OrganaBio

OrganaBio specializes in donor-derived starting materials for cell and gene therapy research and development.

The company’s leukopak portfolio includes fresh and cryopreserved whole leukopaks, as well as downstream PBMC and immune-cell products. OrganaBio reports capabilities for healthy and disease-state donors and offers products across research and cGMP-oriented workflows. 

Its integrated model—from donor sourcing and leukapheresis through cellular processing—illustrates the industry’s movement toward vertically integrated cell-therapy starting-material suppliers.

32. Human Cells Bio

Human Cells Bio represents the growing specialized supplier segment focused on human primary cells and blood-derived research materials.

Companies in this segment support pharmaceutical and biotechnology research by providing human cellular material that can be incorporated into immunology, oncology, cell therapy, biomarker, and drug-development programs. The expanding use of leukopaks as alternatives to smaller-volume blood samples creates additional opportunities for specialized human-cell suppliers.